Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Case 11% Improvement Relative Risk c19hcq.org Rao et al. HCQ for COVID-19 PrEP Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Prospective study of 1,294 patients in India No significant difference in cases Rao et al., Expert Review of Anti-infective Ther.., doi:10.1080/14787210.2022.2015326 Favors HCQ Favors control
Hydroxychloroquine as pre-exposure prophylaxis against COVID-19 infection among healthcare workers: a prospective cohort study
Rao et al., Expert Review of Anti-infective Therapy, doi:10.1080/14787210.2022.2015326
Rao et al., Hydroxychloroquine as pre-exposure prophylaxis against COVID-19 infection among healthcare workers: a.., Expert Review of Anti-infective Therapy, doi:10.1080/14787210.2022.2015326
Dec 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Prospective PrEP study with low risk healthcare workers in India showing RR=0.89 [0.53-1.52]. There were no significant adverse effects. Only mean age and gender distribution are provided for baseline characteristics, no severity information is provided, and no adjustments were made. Authors analyze HCQ use for <8 vs. ≥8 weeks, noting a lack of statistical significance, but not providing the results. This study is excluded in the after exclusion results of meta analysis: unadjusted results with minimal group details.
risk of case, 11.0% lower, RR 0.89, p = 0.68, treatment 16 of 273 (5.9%), control 67 of 1,021 (6.6%), NNT 143.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Rao et al., 4 Dec 2021, prospective, India, peer-reviewed, 8 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Expert Review of Anti-infective Therapy ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/ierz20 Hydroxychloroquine as pre-exposure prophylaxis against COVID-19 infection among healthcare workers: a prospective cohort study Akshay Rao, Sundar Kumar Veluswamy, Banashankari Gunjiganur Shankarappa, Rithika Manjunatha Reddy, Nethravathi Umesh, Lissy John, Lysamma Mathew & Naresh Shetty To cite this article: Akshay Rao, Sundar Kumar Veluswamy, Banashankari Gunjiganur Shankarappa, Rithika Manjunatha Reddy, Nethravathi Umesh, Lissy John, Lysamma Mathew & Naresh Shetty (2021): Hydroxychloroquine as pre-exposure prophylaxis against COVID-19 infection among healthcare workers: a prospective cohort study, Expert Review of Anti-infective Therapy, DOI: 10.1080/14787210.2022.2015326 To link to this article: https://doi.org/10.1080/14787210.2022.2015326 Published online: 20 Dec 2021. Submit your article to this journal Article views: 13 View related articles View Crossmark data Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=ierz20 EXPERT REVIEW OF ANTI-INFECTIVE THERAPY https://doi.org/10.1080/14787210.2022.2015326 ORIGINAL RESEARCH Hydroxychloroquine as pre-exposure prophylaxis against COVID-19 infection among healthcare workers: a prospective cohort study Akshay Rao a, Sundar Kumar Veluswamy b,c, Banashankari Gunjiganur Shankarappad, Rithika Manjunatha Reddye, Nethravathi Umeshf, Lissy Johnf, Lysamma Mathewg and Naresh Shettyh a Department of Internal Medicine, MS Ramaiah Medical College, Bengaluru, India; bDepartment of Physiotherapy, MS Ramaiah Medical College; Healthy Living for Pandemic Event Protection (Hl- Pivot) Network, Chicago, Illinois, USA; dDepartment of Microbiology, MS Ramaiah Medical College; eMedical student, MS Ramaiah Medical College Bengaluru, India; fOffice of Nursing Superintendent, MS Ramaiah Medical College Hospital Bengaluru, India; gOffice of Nursing Superintendent, MS Ramaiah Memorial Hospital, Bengaluru, India; hCaring for the Caregivers Surveillance System, MS Ramaiah Medical College Hospitals c ABSTRACT ARTICLE HISTORY Background: Hydroxychloroquine had attracted significant attention in the initial phases of the COVID19 pandemic but current recommendations do not support its use. However, the evidence against its use as pre-exposure prophylaxis have been of low to moderate quality and have been limited by high risk of bias. Methods: Following institutional ethics committee approval, healthcare workers (n = 1294) completing their first week-long COVID in-patient duty, subsequent institutional quarantine and RT-PCR testing for COVID-19 infection were included for this prospective cohort study. Demographic data, hydroxychlor­ oquine usage and related adverse effects were captured through a ‘Caring for the Caregivers’ surveil­ lance system. A chi-Square test of independence was used to determine the effect of hydroxychloroquine prophylaxis. Results: Among the 1294 participants (age: 31 ± 7 years, 61% women), 273 (21.1%) healthcare workers used hydroxychloroquine prophylaxis as per Indian Council of Medical Research recommendations and 83/1294 (6.4%) tested positive after their duty. There was no significant difference in COVID-19 incidence between those on hydroxychloroquine prophylaxis and those not on it (5.9% vs 6.6%, χ2 = 0.177, p = 0.675; RR = 0.89, 95% CI – 0.53 to 1.52). There were no significant..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit